This suggests that while both drugs cause GI distress, patients might find tirzepatide slightly easier to tolerate long-term. Both drugs carry boxed warnings about the risk of thyroid C-cell tumors based on rodent studies, and neither should be used by patients with a personal or family history of medullary thyroid cancer .